Previous 10 | Next 10 |
home / stock / hbpcf / hbpcf news
--News Direct-- Toronto, Ontario – TheNewswire – June 14, 2023 - Helix BioPharma Corp. (TSX:HBP), (“Helix” or the “Company”), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology based on its propr...
--News Direct-- Toronto, ON - TheNewswire - March 15, 2023 - Helix BioPharma Corp. (TSX:HBP), (“Helix” or the “Company”), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology based on its proprietary technologic...
--News Direct-- Toronto, Ontario – TheNewswire – January 24, 2023 - Helix BioPharma Corp. (TSX:HBP) (“Helix” or the “Company”), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology, based on its propri...
--News Direct-- Toronto, ON - TheNewswire - January 9, 2023 - Helix BioPharma Corp. (TSX:HBP) (“Helix” or the “Company”), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology, based on its proprietary technological ...
--News Direct-- Toronto, Ontario – Thenewswire – December 14, 2022 – Helix BioPharma Corp. (TSX:HBP), (“Helix” or the “Company”), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology based o...
Helix BioPharma ( OTCPK:HBPCF ) said Thursday Jacek Antas has been appointed as CEO to replace Artur Gabor with immediate effect. Gabor resigned as CEO and director. Antas has been on the board since April and has over 25 years of experience in the financial services industry...
--News Direct-- Toronto, ON – TheNewswire - December 8, 2022 - Helix BioPharma Corp. (TSX:HBP) (“Helix” or the “Company”), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology, based on its propriet...
(TheNewswire) NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Toronto, Ontario – TheNewswire – November 3, 2022 - Helix BioPharma Corp. (TSX:HBP) (“Helix” or the “...
Helix Biopharma press release ( OTCPK:HBPCF ): FY GAAP EPS of -$0.04. Net cash of $3.25M For further details see: Helix Biopharma GAAP EPS of -$0.04
--News Direct-- Toronto, Ontario – TheNewswire – November 1, 2022 - Helix BioPharma Corp. (TSX:HBP), (“Helix” or the “Company”), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology based on ...
News, Short Squeeze, Breakout and More Instantly...
Helix Biopharma Corp Company Name:
HBPCF Stock Symbol:
OTCMKTS Market:
Helix Biopharma Corp Website:
SunPower Corporation (SPWR) is expected to report $-0.29 for Q1 2024 Siemens Healthineers AG ADR (SMMNY) is expected to report for Q2 2024 Specificity Inc Com (SPTY) is expected to report for Q1 2024 Tokyo Gas Co. Ltd. ADR (TKGSY) is expected to report for Q4 2024 Gol Linhas Aerea...
Enact Holdings Inc. (ACT) is expected to report $0.99 for Q1 2024 FormFactor Inc. (FORM) is expected to report $0.09 for Q1 2024 SAAB AB - Class B (SAABF) is expected to report for quarter end 2024-03-31 Lumos Pharma Inc. (LUMO) is expected to report $-1.21 for Q1 2024 Axis Capita...
Pegasystems Inc. (PEGA) is expected to report $0.2 for Q1 2024 Masco Corporation (MAS) is expected to report $0.87 for Q1 2024 Avery Dennison Corporation (AVY) is expected to report $2.15 for Q1 2024 Vista Energy S.A.B. de C.V. American Depositary Shares each representing one series A...